About the Company
T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases.
Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development.
Are you passionate about making life science life changing and delivering impact for patients? We want to hear from you.
About the role:
We are a fast-growing biotech start-up focusing on next-generation precision biologics, driven by science, collaboration, and curiosity. We are looking for an Operations Manager to lead the day-to-day operational delivery of the company’s operations, laboratory, and infrastructure processes, ensuring effective execution in line with governance set by the Head of Operations.
- HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease
- Clinical Advisory Board formed to support progression of HRN001 into first-in-human studies in 2027
- Dr Andy Billinton, CSO will present preclinical data at the upcoming CHDI Foundation Huntington’s Disease Therapeutics Conference
As we approach a new financial year, five months on from the launch of the Charities Aid Foundation's latest Corporate Giving Report, its message remains powerful: corporate giving is declining, yet it remains a central pillar to responsible business.
Under the guidance of Alexis De Haven Brandon, we are seeking to recruit a Higher Scientific Officer.
We seek an experienced and dedicated in vivo scientist. The central aim of this position is to undertake in vivo technical work, playing a key role in supporting a variety of in vivo experiments and laboratory approaches. You will be a highly skilled in vivo scientist with sound knowledge and experience in in vivo approaches in a research setting. You will possess a Home Office Personal Licence.
LifeArc Ventures is the venture capital arm of LifeArc and invests globally in innovative, early-stage life sciences companies. LifeArc Ventures invests up to £15m (c.$20m) per company in Seed to Series B opportunities alongside leading global syndicates. The fund is long term capital which draws from LifeArc’s balance sheet derived mainly from Keytruda royalties. Since inception in 2020, the fund has invested in 20 companies including four new companies in 2025.
BioNJ’s BioPartnering Conference is the premier partnering event in New Jersey, where innovative companies go to meet investors and industry representatives.
As the Medicine Chest to the World, New Jersey is home to the world’s top biopharmaceutical companies and an ideal location for this conference for entrepreneurs to meet their next investor or partner. If you are interested in presentingyour company at the 2026 conference, please see details on the website, and be sure to submit your application no later than February 20, 2026.